Clinical Trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Study acronym: RAMP 301
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Protocol Amendment History 94 amendments
This ClinicalTrials.gov record has been amended 94 times since 2023-10-02; most recent amendment 2026-07-24.
Status change: Not Yet Recruiting → Recruiting 2023-12-13
Trial Details
NCT Number NCT06072781
Lead Sponsor Verastem, Inc.
Collaborators: GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Conditions Low Grade Serous Ovarian Cancer
Enrollment 270 participants
Start Date 2024-03-18
Primary Completion 2028-10-15 (estimated)
Study Completion 2031-02-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-14